KR20220038669A - Rna 구조체 - Google Patents

Rna 구조체 Download PDF

Info

Publication number
KR20220038669A
KR20220038669A KR1020227001607A KR20227001607A KR20220038669A KR 20220038669 A KR20220038669 A KR 20220038669A KR 1020227001607 A KR1020227001607 A KR 1020227001607A KR 20227001607 A KR20227001607 A KR 20227001607A KR 20220038669 A KR20220038669 A KR 20220038669A
Authority
KR
South Korea
Prior art keywords
rna
protein
seq
rna construct
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227001607A
Other languages
English (en)
Korean (ko)
Inventor
로빈 샤톡
안나 블래크니
폴 맥케이
Original Assignee
임피리얼 컬리지 이노베이션스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임피리얼 컬리지 이노베이션스 리미티드 filed Critical 임피리얼 컬리지 이노베이션스 리미티드
Publication of KR20220038669A publication Critical patent/KR20220038669A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227001607A 2019-06-18 2020-06-18 Rna 구조체 Pending KR20220038669A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908729.5A GB201908729D0 (en) 2019-06-18 2019-06-18 RNA construct
GB1908729.5 2019-06-18
PCT/GB2020/051465 WO2020254804A1 (en) 2019-06-18 2020-06-18 Rna construct

Publications (1)

Publication Number Publication Date
KR20220038669A true KR20220038669A (ko) 2022-03-29

Family

ID=67432317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227001607A Pending KR20220038669A (ko) 2019-06-18 2020-06-18 Rna 구조체

Country Status (12)

Country Link
US (1) US12569548B2 (https=)
EP (1) EP3987042A1 (https=)
JP (2) JP2022537562A (https=)
KR (1) KR20220038669A (https=)
CN (1) CN114402078B (https=)
AU (1) AU2020296337B2 (https=)
BR (1) BR112021024786A2 (https=)
CA (1) CA3143117A1 (https=)
GB (1) GB201908729D0 (https=)
IL (1) IL288956A (https=)
MX (1) MX2021015753A (https=)
WO (1) WO2020254804A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024181753A1 (ko) * 2023-02-27 2024-09-06 주식회사 마이크로유니 자가 증폭 rna 컨스트럭트 및 이의 용도

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US20210369759A1 (en) * 2020-01-29 2021-12-02 Helix Nanotechnologies, Inc. METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION of NF-kB PATHWAYS AND/OR IRF PATHWAYS
AU2021236068A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4196128A4 (en) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
EP4267593A2 (en) 2020-12-23 2023-11-01 GlaxoSmithKline Biologicals SA Self-amplifying messenger rna
US20240240201A1 (en) 2021-05-04 2024-07-18 Mogrify Limited Cell conversion
CN113249408B (zh) * 2021-06-23 2021-11-02 深圳湾实验室 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
CN118715325A (zh) * 2021-12-17 2024-09-27 帝国理工创新有限公司 Rna构建体
GB202203060D0 (en) 2022-03-04 2022-04-20 Imperial College Innovations Ltd RNA molecule
CN119563028A (zh) * 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
WO2025008641A2 (en) 2023-07-06 2025-01-09 Imperial College Innovations Limited Rna molecule
CN121586776A (zh) * 2023-07-19 2026-02-27 上海复诺健生物科技有限公司 自扩增核酸分子及其应用
GB202313445D0 (en) 2023-09-04 2023-10-18 Imperial College Innovations Ltd Rna molecule
WO2025217136A2 (en) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Trans-amplifying rnas encoding immunomodulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117124A1 (en) 2007-08-31 2011-05-19 Sadoff Jerald C Enhancement of transgene expression from viral-based vaccine vectors by expression of suppressors of the type i interferon response
US7608256B2 (en) 2007-09-12 2009-10-27 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
TR201809547T4 (tr) * 2012-11-09 2018-07-23 Biontech Rna Pharmaceuticals Gmbh Hücresel RNA ifadesine yönelik yöntem.
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
CA3045650A1 (en) * 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024181753A1 (ko) * 2023-02-27 2024-09-06 주식회사 마이크로유니 자가 증폭 rna 컨스트럭트 및 이의 용도

Also Published As

Publication number Publication date
CN114402078B (zh) 2025-11-14
US12569548B2 (en) 2026-03-10
GB201908729D0 (en) 2019-07-31
MX2021015753A (es) 2022-04-12
WO2020254804A1 (en) 2020-12-24
BR112021024786A2 (pt) 2022-02-22
AU2020296337A1 (en) 2021-12-23
EP3987042A1 (en) 2022-04-27
US20220265807A1 (en) 2022-08-25
JP2025118871A (ja) 2025-08-13
IL288956A (en) 2022-02-01
CN114402078A (zh) 2022-04-26
AU2020296337B2 (en) 2025-12-18
CA3143117A1 (en) 2020-12-24
JP2022537562A (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
KR20220038669A (ko) Rna 구조체
AU2024216517A1 (en) Enhanced systems for cell-mediated oncolytic viral therapy
KR102266691B1 (ko) 항원 전달 플랫폼
AU2016333886B2 (en) Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
AU2020229875B2 (en) Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2019375975B2 (en) Artificial expression constructs for selectively modulating gene expression in excitatory cortical neurons
DK2443163T3 (en) POLYMERIZATION OF ISOPREN FROM RENEWABLE RESOURCES
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
KR20210080375A (ko) 암 면역요법을 위한 재조합 폭스바이러스
CN110467679B (zh) 一种融合蛋白、碱基编辑工具和方法及其应用
CN108384784A (zh) 一种利用CRISPR/Cas9技术敲除Endoglin基因的方法
KR20200064980A (ko) 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물
CN110352247A (zh) 用于增强基因表达的组合物和方法
KR20140060541A (ko) 암을 치료하기 위한 rna 조작된 t 세포
KR101891195B1 (ko) 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
KR20240004253A (ko) 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법
KR20180054886A (ko) 변형된 인간 t 세포 수용체 알파 불변 영역 유전자를 포함하는 유전자 변형된 세포
AU2017214656B2 (en) Cancer vaccines and methods of treatment using the same
KR20110076868A (ko) 분리 조건 및/또는 안전한 작업 범위 하에서의 ｃ5 탄화수소가 없는 이소프렌의 제조 방법 및 조성물
KR20110038087A (ko) 재생가능 자원으로부터의 이소프렌 중합체
KR20230066000A (ko) 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼
KR20230134487A (ko) Rna 구조체
CN112771157A (zh) 重组黏液瘤病毒及其用途
KR20220058489A (ko) 인자 vii 요법을 위한 조성물, 디바이스 및 방법
CN112301018B (zh) 新型的Cas蛋白、Crispr-Cas系统及其在基因编辑领域中的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000